EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Erythropoietin alleviates lung ischemia-reperfusion injury by activating the FGF23/FGFR4/ERK signaling pathway

Xiaosheng Jin, Weijing Jin, Guoping Li, Jisheng Zheng, Xianrong Xu

PeerJ · 2024

DOI: 10.7717/peerj.17123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2024. Verfasst von Xiaosheng Jin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China. Hauptthemen laut MEDLINE: Erythropoietin, Reperfusion Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic Public Welfare Research Program of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The purpose of the present study was to investigate the effect of erythropoietin (EPO) on lung ischemia-reperfusion injury (LIRI).

Methods

Sprague Dawley rats and BEAS-2B cells were employed to construct an ischemia-reperfusion (I/R)-induced model in vivo and in vitro , respectively. Afterward, I/R rats and tert-butyl hydroperoxide (TBHP)-induced cells were treated with different concentrations of EPO. Furthermore, 40 patients with LIRI and healthy controls were enrolled in the study.

Results

It was observed that lung tissue damage, cell apoptosis and the expression of BAX and caspase-3 were higher in the LIRI model in vivo and in vitro than in the control group, nevertheless, the Bcl-2, FGF23 and FGFR4 expression level was lower than in the control group. EPO administration significantly reduced lung tissue damage and cell apoptosis while also up-regulating the expression of FGF23 and FGFR4. Rescue experiments indicated that EPO exerted a protective role associated with the FGF23/FGFR4/p-ERK1/2 signal pathway. Notably, the expression of serum EPO, FGF23, FGFR4 and Bcl-2 was decreased in patients with LIRI, while the expression of caspase-3 and BAX was higher.

Conclusion

EPO could effectively improve LIRI, which might be related to the activation of the FGF23/FGFR4/p-ERK1/2 signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErythropoietinReperfusion InjuryAnimalsHumansRatsbcl-2-Associated X ProteinCaspase 3Epoetin AlfaIschemiaLungMAP Kinase Signaling SystemProto-Oncogene Proteins c-bcl-2Rats, Sprague-DawleyReceptor, Fibroblast Growth Factor, Type 4Signal Transduction

Stichwörter der Autor:innen

ErythropoietinFGF23Lung ischemia-reperfusion injury

Substanzen

bcl-2-Associated X ProteinCaspase 3Epoetin AlfaErythropoietinFGFR4 protein, humanProto-Oncogene Proteins c-bcl-2Receptor, Fibroblast Growth Factor, Type 4EPO protein, humanerythropoietin, rat

Autor:innen und Institutionen

  • Pulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
  • Department of Neonatology, Hangzhou Children's Hospital, Hangzhou, China.

Förderung

  • Basic Public Welfare Research Program of Zhejiang Province

Zitieren

APA

Jin, X., Jin, W., Li, G., Zheng, J., & Xu, X. (2024). Erythropoietin alleviates lung ischemia-reperfusion injury by activating the FGF23/FGFR4/ERK signaling pathway. PeerJ. https://doi.org/10.7717/peerj.17123

Vancouver

Jin X, Jin W, Li G, Zheng J, Xu X. Erythropoietin alleviates lung ischemia-reperfusion injury by activating the FGF23/FGFR4/ERK signaling pathway. PeerJ. 2024. doi:10.7717/peerj.17123

BibTeX
@article{Jin2024,
  author = {Jin, Xiaosheng and Jin, Weijing and Li, Guoping and Zheng, Jisheng and Xu, Xianrong},
  title = {Erythropoietin alleviates lung ischemia-reperfusion injury by activating the FGF23/FGFR4/ERK signaling pathway},
  journal = {PeerJ},
  year = {2024},
  doi = {10.7717/peerj.17123}
}
Kostenlos starten →